Lassa fever treatment options
Pro Research Analysisby 
Searched over 200M research papers
Current Lassa Fever Treatment Options: Ribavirin and Supportive Care
The main treatment for Lassa fever is supportive care, which includes managing symptoms and complications as they arise. Ribavirin, an antiviral medication, is the most commonly used drug for treating acute Lassa fever, especially when started early in the course of the disease. However, the evidence supporting ribavirin’s effectiveness is limited and mostly based on a single clinical trial with a high risk of bias. Some studies suggest ribavirin may reduce mortality in patients with severe disease (elevated AST), but it could potentially increase the risk of death in patients with milder forms of Lassa fever, raising concerns about its universal use and highlighting the need for urgent reassessment of its role in treatment Alli2021Eberhardt2019Salam2021+1 MORE.
Investigational and Emerging Therapies for Lassa Fever
Favipiravir and Combination Therapy
Favipiravir, another antiviral, has shown promise in animal studies and has been used in combination with ribavirin in a few human cases, where both patients survived. However, these cases also showed prolonged viral RNA in blood and semen, suggesting the need for further research on its effectiveness and implications for transmission Joseph2022Hansen2021Raabe2017.
Monoclonal Antibody Therapies
Recent advances have led to the development of monoclonal antibody (MAb) therapies targeting the Lassa virus glycoprotein. A cocktail of three human MAbs, known as Arevirumab-3, demonstrated 100% survival in animal models even when administered at advanced stages of disease. These antibody therapies are considered promising and may become key treatment options pending further clinical trials in endemic regions Joseph2022Hansen2021Cross2019+1 MORE.
Other Experimental and Repurposed Drugs
Several other drugs are under investigation for Lassa fever treatment, including:
- LHF-535, a small-molecule antiviral, has shown good safety and pharmacokinetics in early human trials, with exposures predicted to suppress viral replication Joseph2022Amberg2022.
- Other experimental agents such as taribavirin, losmapimod, adamantyl diphenyl piperazine 3.3, Arbidol (umifenovir), and decanoyl-RRLL-chloromethyl ketone (dec-RRLL-CMK) are being explored, but their efficacy and safety in humans remain to be established .
Convalescent Plasma and Other Approaches
Convalescent plasma, derived from recovered Lassa fever patients, has not shown sufficient evidence of benefit and is not currently recommended as a standard treatment Joseph2022Alli2021.
Challenges and Future Directions in Lassa Fever Treatment
There are currently no approved vaccines or highly effective therapeutics for Lassa fever. The genetic diversity of the Lassa virus and its ability to evade the immune system complicate the development of effective treatments and vaccines. Ongoing research is focused on drug repurposing, novel antiviral agents, and targeting viral proteins such as the nucleoprotein (NP) for new therapies Joseph2022Aloke2023.
Conclusion
Lassa fever treatment options remain limited, with ribavirin as the mainstay despite questions about its efficacy and safety. Promising new therapies, including favipiravir, monoclonal antibodies, and novel antivirals like LHF-535, are in development and may improve outcomes in the future. Until more effective treatments and vaccines are available, early diagnosis, supportive care, and preventive measures are critical in managing Lassa fever, especially in endemic regions Joseph2022Hansen2021Cross2019+7 MORE.
Sources and full results
Most relevant research papers on this topic
Ribavirin for the Treatment of Lassa Fever: A Systematic Review and Meta-Analysis.
Ribavirin reduces mortality in Lassa fever patients with elevated aspartate aminotransferase levels, but may increase it in those without elevated levels, requiring urgent reassessment of its role in treatment.
DOI
Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives
Understanding the genetic diversity and immune system evasion of Lassa fever strains is crucial for developing effective vaccines and therapeutics to combat this lethal viral disease.
Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
LHF-535, a potential treatment for Lassa fever, is well-tolerated and shows rapid absorption, a long half-life, and potential to suppress viral replication in healthy adults.
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.
Favipiravir and ribavirin combination effectively treated two Lassa fever cases, but both patients developed transaminitis and had prolonged virus RNA in blood and semen, suggesting sexual transmission of the virus.
DOI